StockData

Eloxx Pharmaceuticals vs Relay Therapeutics

ELOX and RLAY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ELOX and RLAY compare

Relay Therapeutics is the larger company, worth 76 times as much as Eloxx Pharmaceuticals ($3.6B against $47.4M).

Relay Therapeutics grew revenue faster over the last twelve months (23.9% versus −100% for Eloxx Pharmaceuticals).

Relay Therapeutics scores higher on the StockData Score (10 against 7 for Eloxx Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricELOXRLAY
Size and price
Market cap$47.4M$3.6B
Share price$11.74$16.47
Change, 1 year1067170%162%
Change, 5 years−98.1%−44.8%
Beta (5Y)–1.96
Employees7192
StockData Score
Total score710 (better)
Valuation score1 (better)0
Growth score02 (better)
Performance score12 (better)
Health score56 (better)
Dividend score00
Valuation
P/S–349×
P/B1.0× (better)4.1×
Growth
Revenue growth (TTM)−100%23.9% (better)
Revenue growth, 5Y average–−28.6%
Profitability
Operating margin–−2999%
Net margin–−2764%
Return on equity−54.3%−36.8% (better)
Return on invested capital–−37.1%
Financial health
Debt / equity0.000.00
Current ratio3.7418.27 (better)
Altman Z-score−4.6024.86 (better)
Piotroski F-score34 (better)
Dividends and buybacks
Buyback yield0.00%–
Shareholder yield0.00%0.00%
Ownership
Held by institutions71.8%113%
Held by insiders42.6%24.5%
Insider net buying, 12 months–−$129M
Superinvestors holding–1
Short interest, % of float2.3%26.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.